The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Neuropharmacology
Matthew W JohnsonJ E Henningfield

Abstract

This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to guide appropriate schedule placement. Psilocybin, like other 5-HT2A agonist classic psychedelics, has limited reinforcing effects, supporting marginal, transient non-human self-administration. Nonetheless, mushrooms with variable psilocybin content are used illicitly, with a few lifetime use occasions being normative among users. Potential harms include dangerous behavior in unprepared, unsupervised users, and exacerbation of mental illness in those with or predisposed to psychotic disorders. However, scope of use and associated harms are low compared to prototypical abused drugs, and the medical model addresses these concerns with dose control, patient screening, preparation and follow-up, and session supervision in a medical facility. CONCLUSIONS: (1) psilocybin has an abuse po...Continue Reading

Citations

Feb 6, 2018·Psychopharmacology·Mendel KaelenRobin Carhart-Harris
Jul 16, 2019·Journal of Psychopharmacology·Kim Pc KuypersDavid Nutt
Dec 7, 2019·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Shannon Mountain-RayDoreen MacLane-Baeder
Feb 23, 2020·PloS One·Bheatrix BienemannDaniel C Mograbi
Feb 29, 2020·Journal of Psychopharmacology·Daniel RosenbaumEmma Hapke
Mar 15, 2020·The International Journal of Neuropsychopharmacology·Erwin KredietEric Vermetten
May 7, 2020·Regional Anesthesia and Pain Medicine·Joel P CastellanosTimothy Furnish
Jul 7, 2020·Journal of Addictive Diseases·Mathias B Forrester
Jul 11, 2019·Harm Reduction Journal·Thomas AndersonEmma Hapke
Jul 18, 2020·Journal of Psychopharmacology·Carl A RobertsPaul Christiansen
May 29, 2020·Journal of Medical Ethics·William R Smith, Dominic Sisti
Feb 27, 2020·The American Journal of Psychiatry·Collin M ReiffUNKNOWN the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research
Sep 22, 2020·Expert Review of Neurotherapeutics·Hartej GillRoger S McIntyre
May 16, 2019·Journal of Psychopharmacology·Albert Garcia-RomeuMatthew W Johnson
Jul 4, 2019·Drug Metabolism Reviews·Rui Filipe Libânio Osório Marta
Sep 24, 2019·Irish Journal of Psychological Medicine·J R KellyV O'Keane
Sep 15, 2020·Therapeutic Advances in Psychopharmacology·Jacob S AdayEmily K Bloesch
Jul 10, 2019·International Review of Psychiatry·Matthew W Johnson
Sep 15, 2020·Therapeutic Advances in Psychopharmacology·Kim P C Kuypers
Oct 10, 2020·Regional Anesthesia and Pain Medicine·Joel P CastellanosTimothy Furnish
Nov 25, 2020·Molecular Biology Reports·Alec J DiVito, Robert F Leger
Dec 1, 2020·The International Journal of Neuropsychopharmacology·Bashkim KadriuCarlos A Zarate
Aug 31, 2019·Pharmacology & Therapeutics·Simone B Sartori, Nicolas Singewald
Jan 31, 2021·Pharmacology, Biochemistry, and Behavior·M L Shawn Bates, Keith A Trujillo
Feb 2, 2021·The International Journal on Drug Policy·Dimitrios Liokaftos
Mar 16, 2021·Journal of Psychopharmacology·Otto SimonssonPeter S Hendricks
Apr 15, 2021·Proceedings of the National Academy of Sciences of the United States of America·Natalie HesselgraveScott M Thompson
Apr 17, 2021·ACS Pharmacology & Translational Science·Richard J ZeifmanCory R Weissman
May 19, 2021·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Wayne Hall
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Henry LoweLorenzo Gordon
Jun 17, 2021·Irish Journal of Medical Science·Kate CorriganJohn R Kelly
Oct 15, 2020·Psychiatric Services : a Journal of the American Psychiatric Association·Brian Holoyda
Jul 31, 2021·The International Journal on Drug Policy·David B YadenPeter S Hendricks
Oct 6, 2021·Nature Medicine·Mason Marks, I Glenn Cohen
Sep 15, 2021·Journal of Neurochemistry·Urszula KozlowskaMaciej Figiel
Nov 7, 2021·Journal of Neurochemistry·Alaina M JasterJavier González-Maeso
Dec 22, 2021·JAMA : the Journal of the American Medical Association·Mason Marks
Jan 5, 2022·Journal of Psychoactive Drugs·Brianna R AltmanJoseph De Leo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Related Papers

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Matthew W Johnson, Roland R Griffiths
The British Journal of Psychiatry : the Journal of Mental Science
C M BulikK S Kendler
Australian Family Physician
Dan I Lubman, Amanda Baker
© 2022 Meta ULC. All rights reserved